|
Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano A, Garcia-Saenz JA, Cejalvo JM, Herranz J, Torres R, Haba-Rodriguez J, Ayala F, Gomez H, Rojo F, Nielsen TO, Martin M. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine. Clin Cancer Res. 2023 Jan 17;29(2):389-400. doi: 10.1158/1078-0432.CCR-22-2191. PubMed PMID: 36346687; PubMed Central PMCID: PMC9873250.
AÑO: 2023; IF: 10.0
|
36346687
|
Sanchez-Canovas M, Jimenez-Fonseca P, Fernandez Garay D, Cejuela Solis M, Casado Elia D, Coma Salvans E, de la Haba Vacas I, Gomez Sanchez D, Fernandez Montes A, Morales Gimenez R, Biosca Gomez de Tejada M, Arrazubi Arrula V, Sequero Lopez S, Otero Candelera R, Sanchez Cendra C, Justo de la Pena M, Moreno Munoz D, Orillo Sarmiento M, Martinez de Castro E, Garcia Escobar I, Bernal Vidal A, Ortega Moran L, Munoz Martin AJ, Sanchez Bayona R, Martinez Ortiz MJ, Ayala de la Pena F, Vicente V, Carmona-Bayonas A. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study. PLoS One. 2023 May 9;18(5):e0266305. doi: 10.1371/journal.pone.0266305. eCollection 2023. PubMed PMID: 37159465; PubMed Central PMCID: PMC10168567.
AÑO: 2023; IF: 2.9
|
|
Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.
AÑO: 2023; IF: 3.5
|
|
Bueno-Muino C, Echavarria I, Lopez-Tarruella S, Roche-Molina M, Del Monte-Millan M, Massarrah T, Jerez Y, Ayala de la Pena F, Garcia-Saenz JA, Moreno F, Rodriguez-Lescure A, Malon-Gimenez D, Ballesteros Garcia AI, Marin-Aguilera M, Galvan P, Braso-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Pare L, Villacampa G, Prat A, Martin M. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. PubMed PMID: 37103916; PubMed Central PMCID: PMC10141274.
AÑO: 2023; IF: 22.5
|
|
Garcia-Torralba E, Perez Ramos M, Ivars Rubio A, Navarro-Manzano E, Blaya Boluda N, de la Morena Barrio P, Garcia-Garre E, Martinez Diaz F, Chaves-Benito A, Garcia-Martinez E, Ayala de la Pena F. Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer. Cancers (Basel). 2023 May 20;15(10):2846. doi: 10.3390/cancers15102846. PubMed PMID: 37345183; PubMed Central PMCID: PMC10216816.
AÑO: 2023; IF: 4.5
|